[go: up one dir, main page]

WO2003033506A1 - Aminoborane acid derivative and proteasome inhibitory drug containing the same - Google Patents

Aminoborane acid derivative and proteasome inhibitory drug containing the same Download PDF

Info

Publication number
WO2003033506A1
WO2003033506A1 PCT/JP2002/010450 JP0210450W WO03033506A1 WO 2003033506 A1 WO2003033506 A1 WO 2003033506A1 JP 0210450 W JP0210450 W JP 0210450W WO 03033506 A1 WO03033506 A1 WO 03033506A1
Authority
WO
WIPO (PCT)
Prior art keywords
aminoborane
acid derivative
same
proteasome inhibitory
remedy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2002/010450
Other languages
English (en)
French (fr)
Inventor
Hiroaki Satoh
Masahiro Ueno
Yoji Tachibana
Koichi Nakamaru
Ryotaro Kojima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyorin Pharmaceutical Co Ltd
Nisshin Pharma Inc
Original Assignee
Kyorin Pharmaceutical Co Ltd
Nisshin Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Pharmaceutical Co Ltd, Nisshin Pharma Inc filed Critical Kyorin Pharmaceutical Co Ltd
Priority to JP2003536245A priority Critical patent/JPWO2003033506A1/ja
Publication of WO2003033506A1 publication Critical patent/WO2003033506A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/JP2002/010450 2001-10-12 2002-10-08 Aminoborane acid derivative and proteasome inhibitory drug containing the same Ceased WO2003033506A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003536245A JPWO2003033506A1 (ja) 2001-10-12 2002-10-08 アミノボラン酸誘導体およびそれを含有するプロテアソーム阻害薬

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001-314731 2001-10-12
JP2001314731 2001-10-12

Publications (1)

Publication Number Publication Date
WO2003033506A1 true WO2003033506A1 (en) 2003-04-24

Family

ID=19132995

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/010450 Ceased WO2003033506A1 (en) 2001-10-12 2002-10-08 Aminoborane acid derivative and proteasome inhibitory drug containing the same

Country Status (2)

Country Link
JP (1) JPWO2003033506A1 (ja)
WO (1) WO2003033506A1 (ja)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003059898A3 (en) * 2002-01-08 2004-02-26 Eisai Co Ltd Eponemycin and epoxomicin analogs and uses thereof
JP2007502304A (ja) * 2003-08-14 2007-02-08 セファロン、インク． プロテアソーム阻害剤及びそれらを使用する方法
EP2088205A1 (en) 2008-02-11 2009-08-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) PSMB10: A diagnosis marker and therapeutic target of chronic rejection.
CN102127052A (zh) * 2011-01-25 2011-07-20 浙江大学 1,4-苯并二恶烷-2-羧酸的合成方法
KR101441703B1 (ko) 2006-06-19 2014-09-17 오닉스 세라퓨틱스, 인크. 프로테아좀 저해를 위한 펩티드 에폭시케톤
US9126997B1 (en) 2010-09-07 2015-09-08 Northwestern University Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
JP2016172768A (ja) * 2016-06-27 2016-09-29 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤
AU2016202747B2 (en) * 2004-03-30 2017-11-23 Millennium Pharmaceuticals, Inc. Synthesis of boronic ester and acid compounds
CN107474062A (zh) * 2004-03-30 2017-12-15 千禧药品公司 硼的酯和酸化合物的合成
WO2018159628A1 (ja) * 2017-02-28 2018-09-07 国立大学法人北海道大学 アミノ酸型アシルボランおよびその製造方法
US10526351B2 (en) 2008-06-17 2020-01-07 Millennium Pharmaceuticals, Inc. Boronate ester compounds and pharmaceutical compositions thereof
JP2021526159A (ja) * 2018-05-28 2021-09-30 チャンスー チア タイ フェンハイ ファーマシューティカル カンパニー リミテッドＪｉａｎｇｓｕ Ｃｈｉａ Ｔａｉ Ｆｅｎｇｈａｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． ペプチドボロン酸エステル類化合物の合成及び使用
US11241448B2 (en) 2014-05-20 2022-02-08 Millennium Pharmaceuticals, Inc. Methods for cancer therapy
CN116637191A (zh) * 2023-06-01 2023-08-25 山东大学 基于硼中子俘获治疗的无载体自组装纳米粒及其制备方法和应用
JP2025016652A (ja) * 2020-02-18 2025-02-04 ミレニアム ファーマシューティカルズ， インコーポレイテッド プロテアソーム阻害剤

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7524883B2 (en) 2002-01-08 2009-04-28 Eisai R&D Management Co., Ltd. Eponemycin and epoxomicin analogs and uses thereof
WO2003059898A3 (en) * 2002-01-08 2004-02-26 Eisai Co Ltd Eponemycin and epoxomicin analogs and uses thereof
JP4917431B2 (ja) * 2003-08-14 2012-04-18 セファロン、インク． プロテアソーム阻害剤及びそれらを使用する方法
JP2007502304A (ja) * 2003-08-14 2007-02-08 セファロン、インク． プロテアソーム阻害剤及びそれらを使用する方法
CN107474062A (zh) * 2004-03-30 2017-12-15 千禧药品公司 硼的酯和酸化合物的合成
AU2016202747B2 (en) * 2004-03-30 2017-11-23 Millennium Pharmaceuticals, Inc. Synthesis of boronic ester and acid compounds
KR101441703B1 (ko) 2006-06-19 2014-09-17 오닉스 세라퓨틱스, 인크. 프로테아좀 저해를 위한 펩티드 에폭시케톤
EP2088205A1 (en) 2008-02-11 2009-08-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) PSMB10: A diagnosis marker and therapeutic target of chronic rejection.
US10526351B2 (en) 2008-06-17 2020-01-07 Millennium Pharmaceuticals, Inc. Boronate ester compounds and pharmaceutical compositions thereof
US11485746B2 (en) 2008-06-17 2022-11-01 Millennium Pharmaceuticals, Inc. Boronate ester compounds and pharmaceutical compositions thereof
US10604538B2 (en) 2008-06-17 2020-03-31 Millenium Pharmaceuticals, Inc. Boronate ester compounds and pharmaceutical compositions thereof
US9126997B1 (en) 2010-09-07 2015-09-08 Northwestern University Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
CN102127052A (zh) * 2011-01-25 2011-07-20 浙江大学 1,4-苯并二恶烷-2-羧酸的合成方法
US11241448B2 (en) 2014-05-20 2022-02-08 Millennium Pharmaceuticals, Inc. Methods for cancer therapy
JP2016172768A (ja) * 2016-06-27 2016-09-29 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤
JP7244921B2 (ja) 2017-02-28 2023-03-23 国立大学法人北海道大学 アミノ酸型アシルボランおよびその製造方法
JPWO2018159628A1 (ja) * 2017-02-28 2019-12-26 国立大学法人北海道大学 アミノ酸型アシルボランおよびその製造方法
WO2018159628A1 (ja) * 2017-02-28 2018-09-07 国立大学法人北海道大学 アミノ酸型アシルボランおよびその製造方法
JP2021526159A (ja) * 2018-05-28 2021-09-30 チャンスー チア タイ フェンハイ ファーマシューティカル カンパニー リミテッドＪｉａｎｇｓｕ Ｃｈｉａ Ｔａｉ Ｆｅｎｇｈａｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． ペプチドボロン酸エステル類化合物の合成及び使用
JP7314259B2 (ja) 2018-05-28 2023-07-25 チャンスー チア タイ フェンハイ ファーマシューティカル カンパニー リミテッド ペプチドボロン酸エステル類化合物の合成及び使用
JP2025016652A (ja) * 2020-02-18 2025-02-04 ミレニアム ファーマシューティカルズ， インコーポレイテッド プロテアソーム阻害剤
CN116637191A (zh) * 2023-06-01 2023-08-25 山东大学 基于硼中子俘获治疗的无载体自组装纳米粒及其制备方法和应用

Also Published As

Publication number Publication date
JPWO2003033506A1 (ja) 2005-02-03

Similar Documents

Publication Publication Date Title
WO2003033506A1 (en) Aminoborane acid derivative and proteasome inhibitory drug containing the same
WO2005092895A3 (en) Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as orl1-receptor antagonists
MY137944A (en) Specific glucocorticoid compounds having anti-inflammatory activity
EP1396493A4 (en) HETEROCYCLIC COMPOUNDS
WO2009020140A1 (ja) アダマンチルウレア誘導体
WO2005037825A3 (en) Protein kinase inhibitors
WO2005018557A3 (en) Substituted pyridinones
WO2006024486A3 (en) Amide derivatives of 3-phenyl dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents
WO2005060972A3 (en) Pyrrolo [2,3-d] pyrimidine compounds for treating transplant rejection
EP1953154A4 (en) CINNAMIDE COMPOUNDS OF MORPHOLINE TYPE
NZ541974A (en) Nucleotide phosphoramidates as anticancer agents
WO2006005609A3 (de) Substituierte oxindol-derivate und diese enthaltende arzneimittel
NO20055092L (no) Substituerte pyrimidioner
WO2008067119A3 (en) Novel compounds
TW200745034A (en) New compounds
WO2005040171A8 (en) Pyrazolo and imidazo-pyrimidine derivatives
WO2004082581A3 (fr) Application a titre de medicaments de derives de cholest-4-en-3- one, compositions pharmaceutiques les renfermant et nouveaux derives
WO2005115470A3 (fr) COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE β-­CARBOLINE, ET LEUR UTILISATION POUR LE TRAITEMENT DES CANCERS
CA2336412A1 (en) Medicament for treatment of diabetes
TW200616961A (en) Carbostyril compound
EP1634874A4 (en) imidazolidine
GB0205688D0 (en) Chemical compounds
WO2004050035A3 (en) Benzimidazoles and analogs thereof as antivirals
TW200637561A (en) Antitumor agent
TW200616636A (en) Novel compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003536245

Country of ref document: JP

122 Ep: pct application non-entry in european phase